Use of DNA Testing to Help Transition Kidney Transplant Recipients to Belatacept-only Immunosuppression
Status:
Not yet recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
The purpose of the study is to identify kidney transplant patients that can be transitioned
from multi-drug immunosuppression therapy to Belatacept monotherapy, using cell free DNA and
gene expression as markers of immune quiescence. The primary objective will be to determine
if donor derived-cell free DNA (AlloSure) can be utilized to facilitate Belatacept
monotherapy, and to determine if Belatacept is safe and effective as immunosuppression in
kidney transplant recipients. The secondary objective is to determine the utility of AlloMap
as a predictor of immune quiescence and tolerance of immunosuppressive de-escalation to
Belatacept monotherapy, and to evaluate the performance of iBox in predicting adverse
outcomes in patients transitioned to Belatacept monotherapy